WHITE PAPER

Intellectual Property Considerations in Drug Development for Biotech Companies

A Guide to Managing IP Risks and Protecting Innovation

Developing a new drug represents one of the most significant financial and time investments in any industry. The average cost to bring a new pharmaceutical asset to market reaches $2.2 billion, with some analyses suggesting figures approaching $4 billion when accounting for capitalized costs of failures. The development timeline spans 10-15 years from initial discovery to regulatory approval. In this high-stakes environment, intellectual property protection becomes the primary mechanism for securing competitive advantage and ensuring return on investment.

However, IP protection in drug development presents unique challenges. Patent applications typically begin early, even before human trials, to stake claims and secure priority dates. Yet the effective commercial life of most drugs ranges only 7-10 years, not the full 20-year statutory patent term, due to the years consumed during development and regulatory approval. This gap between patent filing and market entry makes strategic IP management essential for maximizing the window of market exclusivity.

Innovation is one thing, but protecting and leveraging the intellectual property to maximize downstream revenue is quite another. Adding an IP focus during development can provide additional insights to improve projects by analyzing options that:

- May help streamline the research process by avoiding dead ends or finding white spaces.
- Could reveal which technologies, compounds, drug products, platforms, indications, formulations have patents associated with them.
- Possibly determine if a new project is eligible for patent protection.

Our expertise and technical capabilities allow us to tailor every engagement to customers' precise needs, whether that's an independent project or an opportunity that cuts across the drug continuum. In addition, by combining our intellectual property experience with the technical expertise of our project team we can deliver a more valuable service to help our customers get the most out of their investment.



Considerations for biotech companies when embarking on the drug development journey:

IP Landscape Analysis

Before investing substantial resources in drug development, biotech companies need a comprehensive understanding of the existing patent landscape in their target therapeutic area. IP landscape analysis provides a systematic overview of all relevant patents, patent applications, and intellectual property documents in a specific technical field. This analysis serves multiple strategic purposes. For small and medium biotech companies with limited IP resources, partnering with organizations that combine technical expertise with IP analysis capabilities can deliver more valuable insights by integrating scientific understanding with patent strategy.

Working with the technical teams, the IP service team can generate a one-time list of the relevant IP documents/data in the technical field and/or monitor the IP documents list for changes. Additionally, they can analyze the relevant IP documents/data and assess patentability options, analyze the white space around the target technology of the customer to identify market opportunities, or lay the foundation for developing strong target technology IP to protect a Customer´s developments.

Prior Art Searches and FTO Reports

One of the most critical IP considerations in drug development is determining whether a new product can be commercialized without infringing existing patents held by others. This assessment, known as Freedom to Operate (FTO) analysis, represents essential risk management for any company planning to invest in drug development. Prior art searches form the foundation of FTO analysis. These searches identify existing patents and published applications that may cover aspects of a planned drug product, including the active pharmaceutical ingredient, formulation, manufacturing process, delivery mechanism, and methods of treatment. The search must cover all relevant jurisdictions where the company plans to develop, manufacture, or sell the product.

Curia can perform prior art searches to assist in a Customer´s Freedom To Operate analysis. Alternatively, we can perform focused prior art searches to support Customers trying to overcome obstacles in the target technology white space.

Design Around Strategies

When prior art searches reveal existing patents that may block a planned drug development program, design around strategies offer a proactive approach to avoiding infringement while still advancing innovation. Design around strategies involve deliberately modifying or improving a product to create a new design that achieves similar therapeutic goals while circumventing patent claims held by others. This strategic approach requires close collaboration between technical development teams and IP specialists.

Early implementation of design around strategies during development offers significant advantages. Ongoing monitoring of competitor patent filings enables companies to make course corrections before investing heavily in approaches that may face IP obstacles. This proactive approach reduces the risk of costly late-stage pivots or abandonment of development programs

Thanks to Curia's expertise in both technical and legal aspects, we are best positioned to develop design around strategies and avoid prior art discovered in the white space analysis early on in development.

IP Protection Strategies

While analyzing existing patents and ensuring Freedom To Operate are defensive IP activities, biotech companies must also develop offensive strategies to protect their own innovations. Strong IP protection serves multiple business purposes: it creates barriers to competitive entry, attracts investor confidence, enables licensing opportunities, and maximizes the value of development programs.

Effective IP protection in drug development requires strategic planning throughout the R&D process. Patent applications should be filed at optimal times to balance several competing pressures. Early filing establishes priority dates and prevents competitors from claiming the same innovations, but premature filing before sufficient experimental data exists can result in weak patents vulnerable to invalidity challenges. The industry standard approach files composition of matter patents for new drug candidates close to initiation of first-in-human studies, providing approximately 10-11 years of remaining patent exclusivity when the drug enters the market.

By working together with the project team during customer´s drug development, Curia can support proactively for developing strategies to protect the anticipated IP. We can further assist by suggesting protection and filing strategies to optimize enforceability.

Integrated Approach: Combining Technical Expertise with IP Strategy

The most effective IP management in drug development emerges from integration of technical scientific expertise with specialized intellectual property knowledge. Technical teams working on drug development make discoveries and generate innovations regularly throughout the research process. Many of these developments represent potentially valuable IP, but they may not be immediately recognized as patentable inventions by scientists focused on research objectives. An integrated approach that embeds IP considerations into the technical development process helps ensure that valuable innovations are identified early and protected appropriately.

Disclaimer

The services provided by Curia are exclusively technical in nature and shall not be construed as or relied upon as legal advice.

Whatever non-technical information that customer could be provided with by Curia during the performance of the services, shall have a merely informative character and shall in no way replace the legal advice necessary for proper strategic decisions of a legal nature.

In the event that, in breach of the above, the customer misconstrued or misinterpreted the nature of the information provided by Curia, Curia declines any liability derived from any client's decision-making based on the information provided during the services provided.

CONTACT US

www.curiaglobal.com

curia